Osaka, Japan

Masahide Ohdan

This inventor holds 1 USPTO granted patent. Top assignee: Shionogi Company Limited. Active years: 2018.


% Patents Active = 100.0

Average Co-Inventor Count = 15.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahide Ohdan: Innovator in Alkylene Derivatives

Introduction

Masahide Ohdan is a notable inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on alkylene derivatives. His research focuses on compounds that exhibit ACC2 inhibiting activity, which has potential therapeutic applications.

Latest Patents

Masahide Ohdan holds a patent for alkylene derivatives, specifically aimed at providing novel compounds with ACC2 inhibiting activity. The patent also includes a pharmaceutical composition comprising these compounds, showcasing his commitment to advancing medical science. He has 1 patent to his name, reflecting his innovative contributions to the industry.

Career Highlights

Ohdan is associated with Shionogi Company Limited, a prominent pharmaceutical company known for its research and development efforts. His work at Shionogi has allowed him to explore and develop new compounds that could lead to significant advancements in treatment options.

Collaborations

Throughout his career, Masahide Ohdan has collaborated with esteemed colleagues, including Masafumi Iwatsu and Keisuke Miyazaki. These collaborations have fostered a productive environment for innovation and have contributed to the success of their research endeavors.

Conclusion

Masahide Ohdan's work in the field of alkylene derivatives exemplifies the impact of innovative research in pharmaceuticals. His contributions, particularly through his patent, highlight the importance of developing new therapeutic options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…